{
    "Trade/Device Name(s)": [
        "ACE Hemoglobin A1c (HbA1c) Reagent"
    ],
    "Submitter Information": "Alfa Wassermann Diagnostic Technologies, LLC",
    "510(k) Number": "K170623",
    "Predicate Device Reference 510(k) Number(s)": [
        "K951361"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LCP"
    ],
    "Summary Letter Date": "January 25, 2018",
    "Summary Letter Received Date": "January 29, 2018",
    "Submission Date": "February 21, 2018",
    "Regulation Number(s)": [
        "21 CFR 864.7470"
    ],
    "Regulation Name(s)": [
        "Assay, Glycosylated Hemoglobin"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Hemoglobin A1c",
        "Total Hemoglobin"
    ],
    "Specimen Type(s)": [
        "Venous whole blood"
    ],
    "Specimen Container(s)": [
        "K2-EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "ACE Alera Clinical Chemistry System",
        "ACE Axcel Clinical Chemistry System"
    ],
    "Method(s)/Technology(ies)": [
        "Latex agglutination inhibition assay",
        "Photometric measurement"
    ],
    "Methodologies": [
        "Antibody-coated latex agglutination inhibition"
    ],
    "Submission Type(s)": [
        "Reagent",
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for ACE Hemoglobin A1c (HbA1c) Reagent, an in vitro diagnostic assay for percent hemoglobin A1c using ACE Alera and ACE Axcel systems",
    "Indications for Use Summary": "Quantitative determination of percent hemoglobin A1c in venous whole blood collected in K2-EDTA tubes to monitor long-term blood glucose control in individuals with diabetes mellitus, for use in clinical and physician office laboratories",
    "fda_folder": "Hematology"
}